pegvaliase


( Last Updated : November 2, 2021)
Generic Name:
pegvaliase
Project Status:
Pending
Therapeutic Area:
Phenylketonuria
Manufacturer:
BioMarin Pharmaceutical Inc.
Call for patient/clinician input open:
Brand Name:
Palynziq
Project Line:
Reimbursement Review
Project Number:
SR0712-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
​For the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management
Fee Schedule:
Pending
Indications:
​For the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.